SonoVascular has developed the SonoThrombectomy™ System, a next-generation ultrasound-facilitated catheter system that treats blood clots more safely and effectively.
This innovative system employs a hybrid mechanical-pharmaco approach, uniquely combining focused ultrasound, microbubbles, and thrombolytic drugs in an integrated catheter to enable precise clot disruption and elimination—without vessel damage, blood loss, or ICU admission.
Microbubbles act as amplifiers under ultrasound activation, mechanically loosening clot fibrin and enhancing drug penetration for superior outcomes.
Venous thromboembolism (VTE)—including deep vein thrombosis (DVT) and pulmonary embolism (PE)—remains a leading cause of morbidity and mortality worldwide.
Current standards of care have significant limitations:
- Mechanical thrombectomy and catheter-directed thrombolysis often cause blood loss and vessel wall trauma
- Anticoagulation alone carries high recurrence rates
- Up to 25% of DVT patients develop chronic post-thrombotic syndrome within five years
- Many procedures require ICU admission
SonoVascular’s SonoThrombectomy™ System addresses these gaps with a transformative approach that delivers safer, more effective clot removal in a single session, improving patient outcomes and reducing healthcare burden.
Leadership Team
- Daniel Estay – CEO
Brings decades of MedTech leadership experience from senior roles at Abbott, Johnson & Johnson, and Becton Dickinson, with deep expertise in vascular and cardiovascular markets. - Luke Harada – COO
Complements CEO with 55+ combined years of MedTech experience focused on vascular markets. - Jacob Ruprecht – VP of Engineering
20+ years in MedTech R&D, driving technical innovation. - Craig Nichols – VP of Clinical & RA/QA
Extensive background in clinical strategy and regulatory affairs.
The team is further strengthened by a world-class Scientific Advisory Board featuring key opinion leaders from University of North Carolina, Northwestern University, Mount Sinai, and Massachusetts General Hospital.
Core Value Proposition
The SonoThrombectomy™ System delivers:
- Novel microbubble-mediated cavitation that mechanically debulks clot and enhances low-dose thrombolytic penetration
- Complete clot elimination in a single session
- Standalone cath lab procedure with no blood loss or vessel trauma
- Low-profile catheter design with optional drug therapy
- No direct competitor offering comparable safety and efficacy
Sales Strategy
- U.S. market covered by dedicated territory managers (max 15 hospitals per rep)
- Full-scale sales force: 140–150 FTEs to reach ~2,000 U.S. hospitals
- International expansion via specialized vascular device distributors
This targeted approach positions SonoVascular to rapidly capture share in a high-need market.
SonoVascular’s capital-efficient model focuses on high-margin disposable sales:
- Single-use SonoThrombectomy™ catheter sold to hospitals at ~ $7,000 ASP
- Ultrasound console sold outright or placed on consignment in high-volume centers, secured by catheter consumption commitments
Recurring revenue from disposables drives strong margins as adoption scales.
Investment Opportunity
SonoVascular is raising $6–8 million in Series A preferred equity to advance clinical and regulatory milestones.
Primary use of funds:
- Support clinical feasibility study for pulmonary embolism (PE)
- Complete design verification/validation testing and GLP animal study to enable FDA approval for DVT pivotal study
This capital will de-risk the platform and position the company for pivotal trials and commercialization.
Clinical Progress & Results
Feasibility study in DVT patients (n=12) delivered compelling outcomes:
- 100% clot reduction in all core lab-adjudicated cases
- No device-related adverse events
- All treated veins patent at 30 days and 6 months
- Significant, sustained improvement in post-thrombotic syndrome (PTS) scores
Upcoming Milestones
- Q2 2026: Submit IDE to FDA
- Q3 2026: Initiate U.S. pivotal DVT study (60–75 patients, 15 centers)
- Q2–Q3 2026: Conduct PE feasibility study
The SonoThrombectomy™ System demonstrates transformative potential to redefine clot management.
To date, SonoVascular has raised ~$9.6 million in private financing through convertible notes since 2022.
Investors include:
- University of North Carolina
- North Carolina State University (Wolfpack Investor Network)
- University of Michigan
- North Carolina Biotechnology Center
Current Raise
| Round | Target Amount | Already Committed |
|---|---|---|
| Series A Preferred Equity | $6–8 million | ~$1.2 million |
